Clearmind Medicine

Company Overview

Snapshot

Founded in January 2021, Clearmind Medicine is a public company with 1–10 employees. The company has raised $16.21M across 6 funding rounds. In November 2025, Clearmind Medicine announced positive top-line results from the first cohort of its FDA-approved Phase I/IIa clinical trial for Alcohol Use Disorder.

Business overview

Clearmind Medicine is a Health Tech & Life Sciences company focused on developing treatments for binge behavior and mental health conditions, including alcohol use disorder, binge eating, and depression. Its core product, MEAI, is designed to provide a euphoric alcohol-like experience while reducing the desire to consume alcoholic beverages, aiming to support individuals struggling with moderation. The company operates within the Pharma & Medical Biotechnology sector, specifically in Drugs Discovery & Development, leveraging biological molecules for therapeutic applications.

Strategic signal

In September 2024, Clearmind Medicine announced the publication of an international patent application for an innovative MDMA-based combination treatment, following a collaboration with SciSparc. This development signals the company's continued innovation in psychedelic-derived therapies and its strategic focus on expanding its intellectual property portfolio for novel mental health treatments, indicating a forward trajectory in drug discovery and development.

Company Intelligence Q&A

What was a significant recent development regarding Clearmind Medicine's intellectual property?

In September 2024, Clearmind Medicine announced the publication of an international patent application for an innovative MDMA-based combination treatment, stemming from its collaboration with SciSparc.

What is the status of Clearmind Medicine's clinical trials for Alcohol Use Disorder?

In November 2025, Clearmind Medicine announced positive top-line results from the first cohort of its FDA-approved Phase I/IIa clinical trial for Alcohol Use Disorder. In October 2025, the company completed the first cohort treatment in this trial and enrolled the last patient for the first cohort.

Has Clearmind Medicine expanded its clinical trial sites for Alcohol Use Disorder?

In November 2025, Clearmind Medicine received final approval to expand its FDA-regulated Phase I/IIa clinical trial for Alcohol Use Disorder at Hadassah Medical Center. In October 2024, the company announced IRB approval for its FDA First-In-Human clinical trial of CMND-100 at a second clinical site.

What was a key strategic partnership for Clearmind Medicine in 2023?

In September 2023, Clearmind Medicine announced a clinical research collaboration with Johns Hopkins University to evaluate CMND-100 in patients with Alcohol Use Disorder.

What is Clearmind Medicine's recent progress in treating cocaine addiction?

In October 2025, Clearmind Medicine advanced its fight against cocaine addiction with the publication of a U.S. patent application for its non-hallucinogenic neuroplastogen MEAI therapy.